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Antimicrobial resistance is recognized as 
a grave threat to global health.1,2 It already 
causes an estimated 700 000 deaths annu-
ally and – without effective action – is pre-
dicted to cause 10 million deaths annually 
by 2050.3 The World Health Organization 
(WHO) has prepared a draft Global action 
plan on antimicrobial resistance that will 
be discussed at this year’s World Health 
Assembly.4 However, more is required if 
the world is to grapple effectively with 
this huge and complex problem. Global 
collective action is required in three areas: 
(i) access, to ensure that the prevention 
tools, diagnostics and therapies needed 
to reduce the infectious disease burden 
are available and affordable to everyone, 
everywhere; (ii) conservation, to reduce 
the need for antimicrobials and ensure 
their responsible use through prevention 
efforts, infection control, surveillance and 
appropriate prescriptions; and (iii) inno-
vation, to develop the next generation of 
antimicrobials, vaccines, diagnostics and 
infection control technologies.
The problem of antimicrobial resis-
tance requires that all three areas be tackled 
simultaneously. Without conservation and 
innovation, universal access will simply 
drive resistance and deplete existing stocks 
of effective antimicrobials. Conservation, 
if pursued alone, will constrict the market 
for antimicrobials, restrict investment and 
innovation in the field and hinder access.5 
Innovation without conservation will waste 
new drugs and diminish the value of invest-
ments. Innovation without better access is 
inequitable. Like the legs of a tripod, each 
area needs the support of the other two. 
However, solving the issues of access, con-
servation and innovation simultaneously 
will require new coordination and financ-
ing mechanisms, some of which must be 
organized globally.
To avert millions of deaths caused by 
treatable infections, access to antimicrobi-
als should be scaled-up for the many people 
worldwide who cannot obtain or afford 
such drugs. Access could be facilitated by 
equitable pricing or licensing models, but 
external resources will be required to sub-
sidize access for the world’s poorest people. 
Such subsidies create common benefit, by 
reducing disease transmission and prevent-
ing reservoirs of resistant pathogens created 
by inconsistent use.
Conservation activities should con-
tinue to be directed by national and local 
governments but global standards are 
needed for surveillance, infection control, 
health-worker training, sales promotion, 
direct-to-consumer advertising and safe-
guards against incentives for overuse.6
Although public innovation funding 
will realistically continue to flow mostly 
from national budgets, stronger coordina-
tion is needed among key research funders 
and commercial investors in innovation. 
Some funding and rewards should also 
be pooled globally. To avoid incentives for 
overuse, rewards will need to be delinked, 
entirely or partially, from volume of sales.7,8 
The financial contributions from countries 
should be differentiated according to their 
means.
Given these global coordination is-
sues, there is a clear role for a binding inter-
national legal framework to encompass the 
issues of access, conservation and innova-
tion. When paired with strong implementa-
tion mechanisms,9 international law repre-
sents the strongest possible way in which 
countries can commit themselves to act.10 
Where and how should this be done? While 
a small number of high-income countries 
could make progress on innovation,11 long-
term success on conservation and access 
requires nearly universal participation. 
Several options could be explored but two 
seem particularly salient and should be 
pursued in parallel. One is the development 
of a new WHO regulation, under Article 
21 of WHO’s Constitution, that is akin to, 
but separate from, the International Health 
Regulations.12 Any Article 21 regulation is 
automatically binding on all WHO’s Mem-
ber States – unless a Member State opts out. 
The second option is the development of a 
new international treaty negotiated under 
the auspices of the United Nations General 
Assembly.
Our future health depends on form-
ing an international legal framework that 
resolves – or at least substantially reduces – 
the problem of antimicrobial resistance. ■
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